Azais H., Frochot C., Betrouni N., Kerdraon O., Collinet P., Mordon S.   A FOLATE-TARGETED PHOTOSENSITIZER TO IMPROVE SPECIFICITY OF INTRAPERITONEAL PHOTODYNAMIC THERAPY OF OVARIAN PERITONEAL METASTASIS. A PRECLINICAL STUDY.  Int. J. Gynecol. Cancer.  2015 ;25 :618-618
Azais H., Bresson L., Bassil A., Katdare N., Merlot B., Houpeau J. L., El Bedoui S., Meurant J. P., Tresch E., Narducci F.   Chemotherapy drug extravasation in totally implantable venous access port systems: how effective is early surgical lavage?.  J. Vasc. Access.  2015 ;16 :31-37

PURPOSE: Totally implantable venous access port systems (TIVAPS) are a widely used and an essential tool in the efficient delivery of chemotherapy. Chemotherapy drug extravasation (CDE) can have dire consequences and will delay treatment. The purpose of this study is to both clarify the management of CDE and show the effectiveness of early surgical lavage (ESL). METHODS: Patients who had presented to the Cancer Center of Lille (France) with TIVAPS inserted between January 2004 and April 2013 and CDE had their medical records reviewed retrospectively. RESULTS: Thirty patients and 33 events were analyzed. Implicated agents were vesicants (51.5%), irritants (45.5%) and non-vesicants (3%). Huber needle malpositionning was involved in 27 cases. Surgery was performed in 97% of cases, 87.5% of which were for ESL with 53.1% of the latter requiring TIVAPS extraction. Six patients required a second intervention due to adverse outcomes (severe cases). Vesicants were found to be implicated in four out of six severe cases and oxaliplatin in two others. Extravasated volume was above 50 ml in 80% of cases. Only one patient required a skin graft. CONCLUSIONS: CDEs should be managed in specialized centers. ESL allows for limited tissue contact of the chemotherapy drug whilst using a simple, widely accessible technique. The two main factors that correlate with adverse outcome seem to be the nature of the implicated agent (vesicants) and the extravasated volume (above 50 ml) leading to worse outcomes. Oxaliplatin should be considered as a vesicant.

Azais H., Betrouni N., Mordon S., Collinet P.   PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY : CURRENT APPLICATIONS IN GYNECOLOGIC ONCOLOGY.  Int. J. Gynecol. Cancer.  2015 ;25 :1224-1224
Azais H., Betrouni N., Kerdraon O., Frochot C., Collinet P., Mordon S.   FISCHER 344 RAT: A PRECLINICAL MODEL FOR EPITHELIAL OVARIAN CANCER FOLATE-TARGETED THERAPY.  Int. J. Gynecol. Cancer.  2015 ;25 :1223-1223

OBJECTIVE: Ovarian cancer prognosis remains dire after primary therapy. Recurrence rates are disappointingly high as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictive factors of recurrences. Folate receptor alpha (FRalpha) shows promising prospects in targeting ovarian cancerous cells. Our aim was to determine if the Fischer model described by Rose et al could be used to evaluate folate-targeted therapies in preclinical studies. METHODS: NuTu-19 epithelial ovarian cancer cell line was used to induce peritoneal carcinomatosis in female Fischer 344 rats. FRalpha expression by NuTu-19 cells was assessed in vitro by immunofluorescence using "Cytospin(R)" protocol. In vitro folate-targeted compound uptake by NuTu-19 cells was evaluated by incubation of FRalpha-positive ovarian cancer cell lines (NuTu-19/SKOV-3/OVCAR-3/IGROV-1) with or without (control) a folate-targeted photosensitizer. Intracellular incorporation was assessed by confocal microscopy. Determination of in vivo FRalpha tissue expression by several organs of the peritoneal cavity was studied by immunohistochemistry. RESULTS: NuTu-19 cells express FRalpha which allows intracellular incorporation of folate-targeted compound by endocytosis. FRalpha is expressed in tumor tissue, ovary, and liver. Peritoneum, colon, small intestine, and kidney do not express the receptor. CONCLUSIONS: Female Fischer 344 rat is an inexpensive reproducible and efficient preclinical model to study ovarian peritoneal carcinomatosis folate-targeted therapies.

Azaïs H., Bauwens J., Servan-Schreiber E., Deruelle P.   [Odon device: A revolution in the field of assisted vaginal delivery?].  J Gynecol Obstet Biol Reprod (Paris).  2015 ;44 :884-6
Azais H., Bassil A., Bresson L., Bogart E., Narducci F., Leblanc E.   EXCLUSIVE INFRAMESENTERIC PARAAORTIC LYMPHADENECTOMY MORBIDITY IN THE PRETHERAPEUTIC STAGING OF LOCALLY ADVANCED CERVIX CANCER PATIENTS WITH A NEGATIVE PARAAORTIC PREOPERATIVE PET IMAGING. A CASE-CONTROL STUDY.  Int. J. Gynecol. Cancer.  2015 ;25 :743-743
Arsene E., Bleu G., Merlot B., Boulanger L., Vinatier D., Kerdraon O., Collinet P.   Implications of a two-step procedure in surgical management of patients with early-stage endometriold endometrial cancer.  J. Gynecol. Oncol..  2015 ;26 :125-133

OBJECTIVE: Since European Society for Medical Oncology (ESMO) recommendations and French guidelines, pelvic lymphadenectomy should not be systematically performed for women with early-stage endometrioid endometrial cancer (EEC) preoperatively assessed at presumed low- or intermediate-risk. The aim of our study was to evaluate the change of our surgical practices after ESMO recommendations, and to evaluate the rate and morbidity of second surgical procedure in case of understaging after the first surgery. METHODS: This retrospective single-center study included women with EEC preoperatively assessed at presumed low- or intermediate-risk who had surgery between 2006 and 2013. Two periods were defined the times before and after ESMO recommendations. Demographics characteristics, surgical management, operative morbidity, and rate of understaging were compared. The rate of second surgical procedure required for lymph node resection during the second period and its morbidity were also studied. RESULTS: Sixty-one and sixty-two patients were operated for EEC preoperatively assessed at presumed low-or intermediate-risk before and after ESMO recommendations, respectively. Although immediate pelvic lymphadenectomy was performed more frequently during the first period than the second period (88.5% vs. 19.4%; p<0.001), the rate of postoperative risk-elevating or upstaging were comparable between the two periods (31.1% vs. 27.4%; p=0.71). Among the patients requiring second surgical procedure during the second period (21.0%), 30.8% did not undergo the second surgery due to their comorbidity or old age. For the patients who underwent second surgical procedure, mean operative time of the second procedure was 246.1+/-117.8 minutes. Third operation was required in 33.3% of them because of postoperative complications. CONCLUSION: Since ESMO recommendations, second surgical procedure for lymph node resection is often required for women with EEC presumed at low- or intermediate-risk. This reoperation is not always performed due to age/comorbidity of the patients, and presents a significant morbidity.

Allayous C., Dalle S., Saiag P., Dutriaux C., Mortier L., Dupuy A., Lesimple T., Bahadoran P., Dalac S., Marie Beylot Barry, Maubec E., Stoebner P. E., Aubin F., Arnault J. P., Verneuil L., Dreno B., Kowal A., Porcher R., Leccia M. T., Lebbe C.   Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase.  J. Clin. Oncol..  2015 ;33
Alkeraye S., Maire C., Templier C., Desmedt E., Mortier L.   Persistent alopecia induced by vismodegib.  J. Am. Acad. Dermatol..  2015 ;72 :AB189-AB189
Alkeraye S., Maire C., Desmedt E., Templier C., Mortier L.   Persistent alopecia induced by vismodegib.  Br. J. Dermatol..  2015 ;172 :1671-1672